Stocktoria
Insight Molecular Diagnostics Inc. IMDX
Insight Molecular Diagnostics Inc. (IMDX) earns a Piotroski F-score of 3/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $4.1M at a -1238.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| IMDX | Insight Molecular Diagnostics Inc. | 3/9 | — | — | — |
| BMRA | BIOMERICA INC | 2/9 | — | — | — |
| CLDX | Celldex Therapeutics, Inc. | 1/9 | 1.9 | — | — |
| CDIO | Cardio Diagnostics Holdings, Inc. | 1/9 | -4.17 | — | — |
| NNNN | Anbio Biotechnology | 4/9 | — | 326.5 | — |
| ICCC | IMMUCELL CORP /DE/ | 6/9 | 2.93 | — | +4.3% |
| TKNO | Alpha Teknova, Inc. | 5/9 | -1.59 | — | +7.4% |
About Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers GraftAssureCore test, a blood test designed to measure dd-cfDNA using a novel PCR-based measurement platform, for potential patient registrants; GraftAssureIQ, a transplant monitoring assay to measure the donor-derived cell-free DNA; and GraftAssureDx, a decentralized transplant monitoring levels of donor-derived cell-free DNA in plasma following kidney transplantation to aid in the assessment of the probability of allograft rejection at the time of testing in conjunction with standard clinical assessments. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. The company was formerly known as OncoCyte Corporation and changed its name to Insight Molecular Diagnostics Inc. in June 2025. Insight Molecular Diagnostics Inc. was incorporated in 2009 and is based in Nashville, Tennessee.
FAQ
Is IMDX financially healthy?
Insight Molecular Diagnostics Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak).
Does IMDX pay a dividend?
No, Insight Molecular Diagnostics Inc. does not currently pay a dividend.
How profitable is IMDX?
In FY2025, Insight Molecular Diagnostics Inc. had a net margin of -1238.5%.
What is the analyst price target for IMDX?
The average Wall-Street price target for Insight Molecular Diagnostics Inc. is $8.33, about 85.2% above the recent price, from 3 analysts.
Is IMDX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Insight Molecular Diagnostics Inc.: a Piotroski F-score of 3/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.